Delayed and sequencial hemolytic uremic syndrome as a complication of Gemcitabine therapy

Gemcitabine-associated hemolytic-uremic syndrome.

BACKGROUND Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported. METHODS A case is presented of a 45-year-old woman on prolonged gemcitabine treatment for ovarian cancer who developed HUS and recovered after drug discontinuation. A mini-review of the literature based on a MEDLINE search follows. RESULTS Including our own...

Gemcitabine induced hemolytic uremic syndrome

BACKGROUND Gemcitabine is frequently used for the treatment of many cancers. Not infrequently it leads to development of hemolytic uremic syndrome, presenting with hemolytic anemia, acute kidney injury and occasionally peripheral edema, livedo reticularis and digital necrosis. CASE REPORT A 78 year old man with non-small cell lung cancer developed uremic syndrome following treatment with mult...

Delayed Hemolytic Uremic Syndrome Presenting as Diffuse Alveolar Hemorrhage

Hemolytic uremic syndrome (HUS) is defined by the triad of mechanical intravascular hemolytic anemia with schistocytosis, thrombocytopenia and acute renal failure. Pulmonary involvement in HUS is known to be rare. We present the case of a 25-year-old male with diffuse alveolar hemorrhage and myocarditis followed by atypical hemolytic uremic syndrome. In this case, successful treatments included...

Gemcitabine-associated Hemolytic-uremic Syndrome: a Case Report

Division of Nephrology, Department of Medicine, Department of Pathology*, Changhua Christian Hospital, Changhua, Taiwan Received: August, 2003 Revised: October, 2003 Accepted: January, 2004 Address reprint request to: Yao-Ko Wen, M.D., Division of Nephrology, Department of Medicine, Changhua Christian Hospital, 135 Nansiao St., Changhua 500, Taiwan Tel: (04) 7238595 ext 3991 Fax: 728923304 E-ma...

Eculizumab for Gemcitabine-Induced Hemolytic Uremic Syndrome: A Novel Therapy for an Emerging Condition